LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.24 9.83

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.95

Max

3.26

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.701
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+154.73% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	56M 924M
Ankstesnė atidarymo kaina	-6.59
Ankstesnė uždarymo kaina	3.24

Naujienos nuotaikos

By Acuity

34%

66%

89 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

4.079 / 4.323 Palaikymas ir pasipriešinimas

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-20 23:31; UTC

Karštos akcijos

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026-05-20 22:52; UTC

Pagrindinės rinkos jėgos

Osisko Shares Fall on Planned Convertible Notes Offering

2026-05-20 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-20 23:44; UTC

Uždarbis

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026-05-20 23:35; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026-05-20 23:30; UTC

Rinkos pokalbiai

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026-05-20 23:15; UTC

Rinkos pokalbiai

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026-05-20 23:14; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026-05-20 23:02; UTC

Rinkos pokalbiai

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 22:27; UTC

Rinkos pokalbiai

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026-05-20 22:14; UTC

Rinkos pokalbiai

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026-05-20 22:10; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026-05-20 22:00; UTC

Uždarbis

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026-05-20 21:38; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026-05-20 21:27; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026-05-20 21:20; UTC

Uždarbis

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026-05-20 21:19; UTC

Uždarbis

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026-05-20 21:18; UTC

Uždarbis

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026-05-20 21:17; UTC

Uždarbis

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026-05-20 21:16; UTC

Uždarbis

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

154.73% į viršų

12 mėnesių prognozė

Vidutinis 7.54 USD 154.73%

Aukščiausias 10 USD

Žemiausias 4.75 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.079 / 4.323Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

89 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.